Header menu link for other important links
X
Rescuing CD4+CD25+ regulatory T-cell functions in rheumatoid arthritis by cytokine-targeted monoclonal antibody therapy
, S. Sibéril, F. Triebel, D.F. Tough, S.V. Kaveri
Published in Elsevier Ltd
2007
PMID: 17631249
Volume: 12
   
Issue: 13-14
Pages: 548 - 552
Abstract
CD4+CD25+ regulatory T cells (Tregs) play a crucial role in controlling the development of autoimmune diseases such as rheumatoid arthritis (RA). However, despite an increased number of Tregs, the persistence of inflammation in the rheumatoid joints suggests that Tregs are unable to suppress ongoing disease, perhaps due to an inhibition of their functions by pro-inflammatory cytokines. Treatment of RA patients with anti-TNF-α monoclonal antibodies such as infliximab and adalimumab has been found to induce and restore the functions of Tregs. Thus, manipulation of the pro-inflammatory environment in the inflamed synovia via neutralization of inflammatory cytokines by monoclonal antibodies could represent a novel therapeutic strategy for restoring the suppressive functions of Tregs and induction and/or expansion of Tregs in order to reinforce tolerance mechanisms. © 2007 Elsevier Ltd. All rights reserved.
About the journal
JournalData powered by TypesetDrug Discovery Today
PublisherData powered by TypesetElsevier Ltd
ISSN13596446
Open AccessNo